BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
54.99
-0.04 (-0.07%)
Mar 20, 2026, 9:54 AM EDT - Market open
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 17 analysts that cover BioMarin Pharmaceutical stock have a consensus rating of "Buy" and an average price target of $87.24, which forecasts a 58.65% increase in the stock price over the next year. The lowest target is $55 and the highest is $119.
Price Target: $87.24 (+58.65%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 6 | 5 | 5 |
| Buy | 9 | 9 | 8 | 8 | 7 | 8 |
| Hold | 7 | 5 | 6 | 6 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 19 | 19 | 20 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $97 → $85 | Strong Buy | Maintains | $97 → $85 | +54.57% | Mar 11, 2026 |
| Barclays | Barclays | Buy Maintains $80 → $105 | Buy | Maintains | $80 → $105 | +90.94% | Mar 4, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $55 | Hold | Reiterates | $55 | +0.02% | Mar 2, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $98 → $104 | Strong Buy | Maintains | $98 → $104 | +89.13% | Feb 26, 2026 |
| Bernstein | Bernstein | Buy Maintains $90 → $94 | Buy | Maintains | $90 → $94 | +70.94% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
3.68B
from 3.22B
Increased by 14.30%
Revenue Next Year
4.11B
from 3.68B
Increased by 11.65%
EPS This Year
4.68
from 1.80
Increased by 159.19%
EPS Next Year
5.62
from 4.68
Increased by 20.22%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.1B | 4.8B | |||
| Avg | 3.7B | 4.1B | |||
| Low | 3.3B | 3.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 27.9% | 31.6% | |||
| Avg | 14.3% | 11.7% | |||
| Low | 1.2% | -11.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.34 | 9.18 | |||
| Avg | 4.68 | 5.62 | |||
| Low | 3.04 | 3.77 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 251.4% | 96.2% | |||
| Avg | 159.2% | 20.2% | |||
| Low | 68.3% | -19.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.